Almac partners to offer ePRO

By Nick Taylor

- Last updated on GMT

Related tags Almac clinical technologies Clinical trial Medicine Epidemiology

Almac has entered into a partnership with to gain PRO and QoL assessments which it believes will help it recruit patients and generate high quality data for regulatory submissions.

Use of electronic patient reported outcomes (ePRO) has been slowly increasing over the past decade and this, coupled to the wide use of quality of life (QoL) assessments in cancer trials, has led to Almac partnering with (functional assessment of chronic illness therapy).

Under the terms of the deal Almac Clinical Technologies will deliver’s PRO and QoL assessments using its IXR platform, which integrates various user interfaces in the collection and processing of clinical trial data.

By using its IXR platform Almac believes it can “significantly broaden​” the patient populations reached by the assessments. Patients will be able to access the questionnaires in a variety of ways, including phones, the internet and handheld devices.

Almac will also utilise the translation services provided by, which has offered the more than 40 questionnaires it has developed into over 45 languages.

The questionnaires developed by include functional assessment of cancer therapy-general (FACT-G). This has been used in 100s of clinical trials for oncology and other therapy areas and indications.

FACT-G, now in its fourth version, is compilation of questions divided up into four QoL sections: physical well-being; social/family well-being; emotional well-being; and functional well-being. Although developed for cancer it has been applied to other chronic illnesses, including HIV.

Joseph Bedford, director of marketing at Almac Clinical Technologies, added: “Almac understands that two of the greatest challenges in clinical trials are recruiting/retaining patients and generating high quality data for regulatory submission​.

The partnership helps us address both challenges by giving Almac access to some of the most notable scales used to gather PRO data and collecting it in a secure, user-friendly way that assures data integrity and quality for our clients​.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more